Capacity buffer of the saliva in children and adolescents with cancer: Variations induced by the administration of metotrexate or cyclophosphamide.
To determine the variations in the levels of capacity buffer of the saliva in children and adolescents with cancer that receiving Metotrexate or cyclophosphamide. A clinical, random-controlled assay was carried out. The sample was composed by 24 children, ages between 2 and 16 years, with diagnostic of Leukemia and Lymphomas attending to The Autonomous Service of University Hospital of Maracaibo and Hospital of Pediatric Specialties. Two groups were conformed to which a sample of saliva was taken before and after the chemotherapy; twelve patients were randomly placed in the G1: patient receiving Metotrexate and twelve in the G2: patient receiving cyclophosphamide. In order to determine the capacity buffer, the CRT Buffer IVOCLAR VIVADENT was used. The capacity salivary buffer did not show significant differences before and after the administration of the cytostatic agents studied. In this study, the Metotrexate or cyclophosphamide administration does not modify the salivary buffer capacity in pediatric patient with cancer.